Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas

被引:64
作者
Engelsen, Ingeborg B. [1 ]
Stefansson, Ingunn
Aksten, Lars A.
Salvesen, Helga B.
机构
[1] Haukeland Univ Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway
[2] Haukeland Univ Hosp, Dept Pathol, N-5021 Bergen, Norway
[3] Univ Bergen, Gade Inst, Bergen, Norway
[4] Univ Bergen, Inst Clin Med, Bergen, Norway
关键词
endometrial carcinoma; curettage material; tumor markers; prognosis; survival;
D O I
10.1016/j.ajog.2006.02.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to investigate the prognostic impact of p53 and p16 expression in curettage material from patients with endometrial carcinoma. Study design: Preoperative curettage material from a population-based series of 236 endometrial carcinomas from Norway with long and complete follow-up was studied immunohistochemically for p53 and p 16 expression. Results: Pathologic expression of p53 and p16 was seen in 24% and 25%, respectively, and was significantly correlated with high International Federation of Gynecology and Obstetrics (FIGO) stage and serous/clear cell histologic subtypes. Pathologic p53 expression showed significant correlation with postmenopausal status, high grade, high tumor cell proliferation, and aneuploidy. Patients with normal expression had 85% 5-year survival compared with 51% and 50% when pathologic expression of p53 and p16, respectively. Five-year survival for patients with 2 pathologic markers was 13%, compared with 67% and 91% for 1 or no pathologic markers, respectively. Conclusion: Pathologic expression of p53 and p16 in curettage material identifies high-risk endometrial carcinoma patients with poor prognosis. (c) 2006 Mosby, Inc. All rights reserved.
引用
收藏
页码:979 / 986
页数:8
相关论文
共 32 条
[11]  
*I EP CANC RES, 1999, CANC REG NORW CANC N
[12]   Cell-cycle control and its watchman [J].
Jacks, T ;
Weinberg, RA .
NATURE, 1996, 381 (6584) :643-644
[13]  
KILGORE LC, 2005, INT J GYNECOL CANCER, V15, P406
[14]   RELIABILITY OF TUMOR TYPING OF ENDOMETRIAL CARCINOMA IN PREHYSTERECTOMY CURETTAGE [J].
LAMPE, B ;
KURZL, R ;
HANTSCHMANN, P .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1995, 14 (01) :2-6
[15]   COMPARISON OF D-AND-C AND OFFICE ENDOMETRIAL BIOPSY IN PREDICTING FINAL HISTOPATHOLOGIC GRADE IN ENDOMETRIAL CANCER [J].
LARSON, DM ;
JOHNSON, KK ;
BROSTE, SK ;
KRAWISZ, BR ;
KRESL, JJ .
OBSTETRICS AND GYNECOLOGY, 1995, 86 (01) :38-42
[16]   Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation [J].
Lax, SF ;
Pizer, ES ;
Ronnett, BM ;
Kurman, RJ .
HUMAN PATHOLOGY, 1998, 29 (09) :924-931
[17]   SURGICAL PATHOLOGICAL STAGING IN APPARENT STAGE-I ENDOMETRIAL CARCINOMA [J].
MANGIONI, C ;
DEPALO, G ;
MARUBINI, E ;
DELVECCHIO, M .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1993, 3 (06) :373-384
[18]   Endometrial cancer: can nodal status be predicted with curettage? [J].
Mariani, A ;
Sebo, TJ ;
Katzmann, JA ;
Roche, PC ;
Keeney, GL ;
Lesnick, TG ;
Podratz, KC .
GYNECOLOGIC ONCOLOGY, 2005, 96 (03) :594-600
[19]   Pretreatment assessment of prognostic indicators in endometrial cancer [J].
Mariani, A ;
Sebo, TJ ;
Katzmann, JA ;
Keeney, GL ;
Roche, PC ;
Lesnick, TG ;
Podratz, KC .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 182 (06) :1535-1543
[20]  
NORUSIS M, 1994, SPSS ADVANCED STAT 6